Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sticking it to KRAS: Covalent Inhibitors Enter the Clinic.

Cancer cell - 13 Jan 2020

McCormick Frank

Abstract excerpt

Drugs that target KRAS 12C covalently, AMG 510 and MRTX849, are now in the clinic. Recent papers describe development of these compounds, their selectivity and properties, early clinical data, and potential combination therapies. These papers herald a new era in Ras research, with improved drugs and strategies certain to follow.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Design
Share to Drug Evaluation, Preclinical
Share to Genes, ras

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Share to Translational Research, Biomedical

Source

Open in PubMed Open full text

Identifiers

PMID: 31951561
DOI: 10.1016/j.ccell.2019.12.009
PMCID: PMC7891852

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sticking it to KRAS: Covalent Inhibitors Enter the Clinic.PMID 31951561Read ↗

Hitting KRAS When It's Down.Semantic proximity Read ↗

KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.Semantic proximity Read ↗

KRAS inhibitors: resistance drivers and combinatorial strategies.Semantic proximity Read ↗

Eliminating oncogenic RAS: back to the future at the drawing board.Semantic proximity Read ↗

RAS G12C Inhibitors: Three Birds with One Stone.Semantic proximity Read ↗

KRAS inhibitors: going noncovalent.Semantic proximity Read ↗

Stopping the beating heart of cancer: KRAS reviewed.Semantic proximity Read ↗

"Undruggable KRAS": druggable after all.Semantic proximity Read ↗

Drugging RAS: Moving Beyond KRASG12C.Semantic proximity Read ↗

Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.Semantic proximity Read ↗

Drugging the Undruggable: Advances on RAS Targeting in Cancer.Semantic proximity Read ↗

The path to the clinic: a comprehensive review on direct KRASG12C inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.